8-K: TELA Bio Appoints Dr. Betty Jo Rocchio to Board

TELA Bio, Inc. announced the resignation of Lisa Colleran from its Board of Directors and the appointment of Dr. Betty Jo Rocchio as a new independent director.

Summary

• Lisa Colleran resigned from TELA Bio, Inc.'s Board of Directors, Nominating and Corporate Governance Committee, and Audit Committee, effective October 4, 2025.
• Ms. Colleran's resignation was not due to any disagreement with the company's operations, policies, or practices.
• Dr. Betty Jo Rocchio was appointed to the Board as a Class I director, effective October 9, 2025, with her term expiring at the 2026 Annual Meeting of Stockholders.
• Dr. Rocchio, 57, currently serves as Executive Vice President, Chief Executive Nurse at Advocate Health, overseeing 165,000 full-time employees, including 42,000 registered nurses.
• Her prior experience includes Senior Vice President, Chief Nurse Executive at Mercy Health System from October 2020 to November 2024, and other leadership roles at Mercy.
• The Board determined Dr. Rocchio is an independent director under Nasdaq listing rules, with no related party transactions or family relationships with existing directors or officers.
• Dr. Rocchio received an initial equity award on October 9, 2025, consisting of an option to purchase 17,550 shares (vesting over 36 months) and a restricted stock unit award for 11,925 shares (vesting over three years).
• She will receive an annual base retainer of $45,000 for her Board service.
• Beginning at the 2026 Annual Meeting, Dr. Rocchio will receive an annual award of an option to purchase 11,700 shares and a restricted stock unit award for 7,950 shares, vesting on the earlier of the first anniversary, subsequent annual meeting, or a change in control.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a director's resignation is a change, the explicit statement of no disagreement mitigates potential negative interpretations. The appointment of a highly experienced and independent director like Dr. Rocchio is a positive step for corporate governance and strategic insight, contributing to a net positive outlook.

Positives

• The appointment of Dr. Betty Jo Rocchio brings extensive healthcare leadership and nursing expertise to the Board, enhancing strategic oversight in a relevant industry.
• Dr. Rocchio's independence, as determined by Nasdaq listing rules, strengthens corporate governance and ensures objective decision-making.
• The company explicitly stated that Lisa Colleran's resignation was not due to any disagreements, suggesting a smooth transition and stability in company operations and policies.

Negatives

• The resignation of an experienced director, Lisa Colleran, from the Board and two key committees (Nominating and Corporate Governance, and Audit) represents a loss of institutional knowledge and continuity, despite the stated lack of disagreement.

Future Outlook

Dr. Rocchio's term as a Class I director will expire at the Company's 2026 Annual Meeting of Stockholders. She will also receive annual equity awards starting from the 2026 Annual Meeting, subject to continued service.

Management Comments

• Ms. Colleran's decision to resign did not result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.

Industry Context

The appointment of Dr. Betty Jo Rocchio, with her extensive background as a Chief Executive Nurse in large integrated health systems like Advocate Health and Mercy Health System, aligns TELA Bio with a director who possesses deep operational and strategic insights into the healthcare delivery landscape. This is particularly relevant for a company in the medical technology sector, as it provides a direct link to the perspectives and needs of major healthcare providers and their patient populations.

Comparison to Industry Standards

• The compensation package for Dr. Rocchio, including an annual base retainer of $45,000 and initial and annual equity awards, appears to be within the typical range for non-employee directors at publicly traded companies of similar size and market capitalization in the medical technology sector. However, without specific peer company data, a precise comparison is not feasible.
• The practice of granting equity awards that vest over time and are tied to continued service is a standard industry practice designed to align director interests with long-term shareholder value.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced and independent director like Dr. Rocchio is generally positive for corporate governance and strategic oversight, potentially enhancing long-term shareholder value. The explicit statement that Ms. Colleran's resignation was not due to disagreement should reassure investors about board stability.

Next Steps

• Dr. Rocchio will serve as a Class I director until the Company's 2026 Annual Meeting of Stockholders.
• Dr. Rocchio will begin receiving annual equity awards starting at the Company's 2026 Annual Meeting of Stockholders.

Key Dates

Recommendation

The filing details routine board changes, including a resignation and the appointment of a new, experienced independent director. These changes do not fundamentally alter the company's financial outlook or strategic direction, warranting a 'hold' recommendation. While the new director brings valuable expertise, the overall impact on the company's immediate operational or financial performance is not expected to be significant enough to warrant a 'buy' or 'sell' action based solely on this filing.

Keywords

TELA Bio, Board of Directors, Director Appointment, Corporate Governance, Healthcare, Nasdaq, Executive Leadership, Medical Technology